Gilbert G G Donders1,2,3, Svitrigaile Grinceviciene4, Kai Haldre5, Risa Lonnee-Hoffmann6, Francesca Donders1, Aristotelis Tsiakalos7, Albert Adriaanse8, José Martinez de Oliveira9, Kevin Ault10, Werner Mendling11. 1. Femicare VZW Clinical Research for Women, 3300 Tienen, Belgium. 2. Department Obstetrics and Gynecology, University Hospital Antwerp, 2650 Edegem, Belgium. 3. President International Society Infectious Diseases (ISIDOG), 3300 Tienen, Belgium. 4. Department Biothemodynamics and Drug Design, Institute of Biotechnology and Life Sciences Center, Vilnius University, 01513 Vilnius, Lithuania. 5. East Tallin Central Hospital Women's Clinic, 10138 Tallin, Estonia. 6. Department Gynecology, Hospital St Olav, 7030 Trondheim, Norway. 7. LETO-Obstetrician Gynecological & Surgical Center, Department Obstetrics and Gynecology, 11525 Athens, Greece. 8. Medisch Centrum Alkmaar, Department Obstetrics and Gynecology, 1814 Alkmaar, The Netherlands. 9. Department Obstetrics and Gynecology, Universidade da Beira Interior, 6201-001 Covilha, Portugal. 10. Department Obstetrics and Gynecology, University of Kansas Medical Center, Kansas City, KS 66160, USA. 11. German Center for Infections in Obstetrics and Gynceology, Department Obstetrics and Gynecology, 42283 Wupperthal, Germany.
Abstract
INTRODUCTION: Sars-CoV-2 infection poses particular problems in pregnancy, as the infection more frequently causes severe complications than in unaffected pregnant women or nonpregnant women with SARS-CoV-2 infection. Now that vaccination is available and rapidly being implemented worldwide, the question arises whether pregnant women should be vaccinated, and if so, whether they should receive priority. METHODS: Available scientific data and available guidelines about vaccination against SARS-CoV-2 were collected by the Guideline Committee of the International Society of Infectious Diseases in Obstetrics and Gynecology (ISIDOG) and were analyzed, discussed and summarized as guidelines for healthcare workers caring for pregnant women. Concluding statements were graded according to the Oxford evidence-based medicine grading system. RESULTS: There is evidence to consider pregnancy as a risk factor for serious complications of COVID-19 infection, even in the absence of additional risk factors, such as hypertension, diabetes and obesity which increase these risks even more in pregnancy. Currently available data slightly favor mRNA-based vaccines above vector-based vaccines during pregnancy and breastfeeding, until more safety data become available. CONCLUSION: ISIDOG advises policy makers and societies to prioritize pregnant women to receive vaccination against SARS-CoV-2 and favor the mRNA vaccines until further safety information becomes available.
INTRODUCTION:Sars-CoV-2 infection poses particular problems in pregnancy, as the infection more frequently causes severe complications than in unaffected pregnant women or nonpregnant women with SARS-CoV-2 infection. Now that vaccination is available and rapidly being implemented worldwide, the question arises whether pregnant women should be vaccinated, and if so, whether they should receive priority. METHODS: Available scientific data and available guidelines about vaccination against SARS-CoV-2 were collected by the Guideline Committee of the International Society of Infectious Diseases in Obstetrics and Gynecology (ISIDOG) and were analyzed, discussed and summarized as guidelines for healthcare workers caring for pregnant women. Concluding statements were graded according to the Oxford evidence-based medicine grading system. RESULTS: There is evidence to consider pregnancy as a risk factor for serious complications of COVID-19infection, even in the absence of additional risk factors, such as hypertension, diabetes and obesity which increase these risks even more in pregnancy. Currently available data slightly favor mRNA-based vaccines above vector-based vaccines during pregnancy and breastfeeding, until more safety data become available. CONCLUSION: ISIDOG advises policy makers and societies to prioritize pregnant women to receive vaccination against SARS-CoV-2 and favor the mRNA vaccines until further safety information becomes available.
Authors: Luigi Carbone; Raffaella Di Girolamo; Ilenia Mappa; Gabriele Saccone; Antonio Raffone; Daniele Di Mascio; Valentino De Vivo; Francesco D'Antonio; Maurizio Guida; Giuseppe Rizzo; Giuseppe Maria Maruotti Journal: Eur J Obstet Gynecol Reprod Biol Date: 2021-12-07 Impact factor: 2.435
Authors: Raffaella Di Girolamo; Asma Khalil; Giuseppe Rizzo; Giulia Capannolo; Danilo Buca; Marco Liberati; Ganesh Acharya; Anthony O Odibo; Francesco D'Antonio Journal: Am J Obstet Gynecol MFM Date: 2022-05-02